Eliquis gains European approval in stroke prevention
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Pfizer's oral direct Factor Xa inhibitor, Eliquis (apixaban), has been approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, in Europe, its first market for this second approved indication.